Familial prevalence and age of RET germline mutations: Implications for screening

Clinical Endocrinology

Volumn 69, Issue 1, 2008, Pages 81-87

  Machens, Andreas ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CODON; CONTROLLED STUDY; DNA SCREENING; ENDOCRINE TUMOR; EXON; FAMILIAL DISEASE; FEMALE; GENE REARRANGEMENT; GENETIC SCREENING; GENETIC TRANSFECTION; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; PHENOTYPE; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

EVOLUTION, MOLECULAR; FAMILY; GENE FREQUENCY; GENETIC SCREENING; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-RET; TIME FACTORS;

EID: 45349087430     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03153.x     Document Type: Article

References (37)

1. Eng, C. (1996) The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. New England Journal of Medicine, 335, 943 951.
2. Donis-Keller, H., Dou, S., Chi, D., Carlson, K.M., Toshima, K., Lairmore, T.C., Howe, J.R., Moley, J.F., Goodfellow, P. Wells, S.A. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics, 2, 851 856.
3. Mulligan, L.M., Kwok, J.B.J., Healey, C.S., Elsdon, M.J., Eng, C., Gardner, E., Love, D.R., Mole, S.E., Moore, J.K., Papi, L., Ponder, M.A., Telenius, H., Tunnacliffe, A. Ponder, B.A.J. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363, 458 460.
4. Santoro, M., Carlomagno, F., Romano, A., Botaro, D.P., Dathan, N.A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M.H. Di Fiore, P.P. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science, 267, 381 383.
5. Pasini, A., Geneste, O., Legrand, P., Schlumberger, M., Rossel, M., Fournier, L., Rudkin, B.B., Schuffenecker, I., Lenoir, G.M. Billaud, M. (1997) Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene, 15, 393 402.
6. Menacho, I.P., Koster, R., Van der Sloot, A.M., Quax, W.J., Osinga, J., Van der Sluis, T., Hollema, H., Burzynski, G.M., Gimm, O., Buys, C.H.C.M., Eggen, B.J.L. Hofstra, R.M.W. (2005) RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Research, 65, 1729 1737.
7. Brandi, M.L., Gagel, R.F., Angeli, A., Bilezikian, J.P., Beck-Peccoz, P., Bordi, C., Conte-Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J.M., Lombardi, G., Mannelli, M., Pacini, F., Ponder, B.A.J., Raue, F., Skogseid, B., Tamburrano, G., Thakker, R.V., Thompson, N.W., Tomassetti, P., Tonelli, F., Wells, S.A. Marx, S.J. (2001) Guideline for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism, 86, 5658 5671.
8. Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T.J., Roeher, H.D., Wahl, R.A., Lamesch, P., Raue, F., Conte-Devolx, B. Dralle, H. for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group (2003) Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine, 349, 1517 1525.
9. Machens, A., Holzhausen, H.J., Thanh, P.N. Dralle, H. (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery, 134, 425 431.
10. Machens, A., Brauckhoff, M., Holzhausen, H.J., Thanh, P.N., Lehnert, H. Dralle, H. (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism, 90, 3999 4003.
11. Ritter, M.M. Höppner, W. (2001) Multiple endocrine Neoplasie Typ 2. In : D. Ganten, K. Ruckpaul eds. Molekularmedizinische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin, 123 138.
12. Siggelkow, H., Melzer, A., Nolte, W., Karsten, K., Höppner, W. Hüfner, M. (2001) Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low-grade malignancy. European Journal of Endocrinology, 144, 467 473.
13. Simon, S., Pavel, M., Hensen, J., Berg, J., Hümmer, H.P. Carbon, R. (2002) Multiple endocrine neoplasia 2A syndrome: surgical management. Journal of Pediatric Surgery, 37, 897 900.
14. Loré, F., Talidis, F., di Cairano, G. Renieri, A. (2001) Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. Journal of Internal Medicine, 250, 37 42.
15. Lindskog, S., Nilsson, O., Jansson, S., Nilsson, B., Illerskog, A.C., Ysander, L., Ahlman, H. Tisell, L.E. (2004) Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618. British Journal of Surgery, 91, 713 718.
16. Hansen, H.S., Tørring, H., Godballe, C., Jäger, A.C. Nielsen, F.C. (2000) Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? Cancer, 89, 863 867.
17. Berndt, I., Reuter, M., Saller, B., Frank-Raue, K., Groth, P., Grußendorf, M., Raue, F., Ritter, M.M. Höppner, W. (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism, 83, 770 774.
18. Colombo-Benkmann, M., Brämswig, J., Höppner, W., Gellner, R., Hengst, K., Böcker, W. Senninger, N. (2002) Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia. World Journal of Surgery, 26, 1286 1290.
19. Learoyd, D.L., Gosnell, J., Elston, M.S., Saurine, T.J., Richardson, A.L., Delbridge, L.W., Conaglen, J.V. Robinson, B.G. (2005) Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clinical Endocrinology, 63, 636 641.
20. Neumann, H.P.H., Vortmeyer, A., Schmidt, D., Werner, M., Erlic, Z., Cascon, A., Bausch, B., Januszewicz, A. Eng, C. (2007) Evidence of MEN-2 in the original description of classic pheochromocytoma. New England Journal of Medicine, 357, 1311 1315.
21. Schuffenecker, I., Ginet, N., Goldgar, D., Eng, C., Chambe, B., Boneu, A., Houdent, C., Pallo, D., Schlumberger, M., Thivolet, C. Lenoir, G.M. (1997) Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs à Calcitonine. American Journal of Human Genetics, 60, 233 237.
22. Gardner, E., Mulligan, L.M., Eng, C., Healey, C.S., Kwok, J.B., Ponder, M.A. Ponder, B.A.L. (1994) Haplotype analysis of MEN 2 mutations. Human Molecular Genetics, 3, 1171 1174.
23. Pinna, G., Orgiana, G., Riola, A., Ghiani, M., Lai, M.L., Carcassi, C. Mariotti, S. (2007) RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid, 17, 101 104.
24. Hudson, K.L. (2007) Prohibiting genetic discrimination. New England Journal of Medicine, 356, 2021 2023.
25. Bugalho, M.J., Domingues, R., Santos, J.R., Catarino, A.L. Sobrinho, L. (2007) Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery, 141, 90 95.
26. Williams, E.D. (1966) Histogenesis of medullary carcinoma of the thyroid. Journal of Clinical Pathology, 19, 114 118.
27. Hazard, J.B., Hawk, W.A. Crile, G.J. (1959) Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. Journal of Clinical Endocrinology and Metabolism, 19, 152 161.
28. De Braekeleer, M. Gauthier, S. (1996) Autosomal recessive disorders in Saguenay-Lac-St-Jean, Quebec: study of kinship. Human Biology, 68, 371 381.
29. Niccoli-Sire, P., Murat, A., Rohmer, V., Franc, S., Chabrier, G., Baldet, L., Maes, B., Savagner, F., Giraud, S., Bezieau, S., Kottler, M.L., Morange, S., Conte-Devolx, B. The French Calcitonin Tumors Study Group (GETC 2001) Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism, 86, 3746 3753.
30. Elisei, R., Romei, C., Cosci, B., Agate, L., Bottici, V., Molinaro, E., Sculli, M., Miccoli, P., Basolo, F., Grasso, L., Pacini, F. Pinchera, A. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Journal of Clinical Endocrinology and Metabolism, 92, 4725 4729.
31. Baumgartner-Parzer, S.M., Lang, R., Wagner, L., Heinze, G., Niederle, B., Kaserer, K., Waldhäusl, W. Vierhapper, H. (2005) Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism, 90, 6232 6236.
32. Jindrichová, S., Vcelák, J., Vlcek, P., Neradilová, M., Nemec, J. Bendlová, B. (2004) Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. Journal of Endocrinology, 183, 257 265.
33. Vestergaard, P., Vestergaard, E.M., Brockstedt, H. Christiansen, P. (2007) Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated? World Journal of Surgery, 31, 996 1001.
34. Arum, S.H., Dahia, P.L., Schneider, K. Braverman, L.E. (2005) A RET mutation with decreased penetrance in the family of a patient with a 'sporadic' pheochromocytoma. Endocrine, 28, 193 198.
35. Tamanaha, R., Camacho, C.P., Ikejiri, E.S., Maciel, R.M.B. Cerutti, J.M. (2007) Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants. Clinical Endocrinology, 67, 805 808.
36. Gilchrist, D.M., Morrish, D.W., Bridge, P.J. Brown, J.L. (2004) Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2. Clinical Genetics, 66, 349 353.
37. Paszko, Z., Sromek, M., Czetwertynska, M., Skasko, E., Czapczak, D., Wisniewska, A., Prokurat, A., Chrupek, M., Jagielska, A. Kozlowicz-Gudzinska, I. (2007) The occurence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindreds from Central Poland. Cancer Investigation, 25, 742 749.